Medical News

RSS

Melanoma risk rises with the use of sunbeds: Study

According to an Australian Melanoma Family study, use of sunbeds to get a tan can increase the risk of developing melanoma by 41 per cent. The study looked into the effects of sunbeds on 18-39-year-olds and found that 23 per cent of participants who had melanoma reported using these machines.

5 Aug 2010

Australia has highest rates of type 1 diabetes among children

Australia ranks the highest among 10 OECD countries when it comes to rate of type 1 diabetes among children, according to the Australian Institute of Health and Welfare (AIHW). The OECD or consists of 32 countries.

5 Aug 2010

Anti-vaccine group accused of unauthorized fundraising

The Australian Vaccination Network is involved in controversy yet again. The Bangalow-based anti-vaccination group has been given a timeline of 28 days to answer to claims that it breached charitable fundraising legislation on several occasions. It was only last month that the Health Care Complaints Commission had accused AVN of spreading misleading information about the dangers of immunization through its website.

5 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

Ligand second-quarter net loss reduces to $0.3 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and six months ended June 30, 2010 and provided an update on key programs.

5 Aug 2010

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail Corporation today announced financial results for the three-month and six-month periods ended June 30, 2010.

5 Aug 2010

WebMD intends to commence share repurchase program

WebMD Health Corp. announced today that it intends to commence a tender offer next week to purchase up to 3,000,000 shares of its common stock at a price per share of $50.00. The number of shares proposed to be purchased in the tender offer represents approximately 5.2% of WebMD's currently outstanding common shares. The NASDAQ Official Closing Price of WebMD's common stock on August 4, 2010 was $47.25 per share.

5 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Sunrise Senior Living reports net income of $46.3 million for second-quarter 2010

Sunrise Senior Living, Inc. today reported financial results and operating data for the second quarter of 2010.

5 Aug 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM BioSciences Inc., announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis. In total, 21 patients were treated in Phase I, with no voluntary withdrawals reported. CYT387 has shown significant activity in reducing spleen size and controlling constitutional symptoms in these patients.

5 Aug 2010

Harvard Bioscience second-quarter revenues increase 43.5% to $25.9 million

Harvard Bioscience, Inc., a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the three and six months ended June 30, 2010.

From Harvard Bioscience 5 Aug 2010

Biovail declares quarterly dividend of US$0.095

Biovail Corporation today announced that the Company's Board of Directors has declared a quarterly cash dividend of US$0.095.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Watson Pharmaceuticals, Inc. today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009. GAAP earnings for the second quarter 2010 were $0.57 per share, compared to $0.46 per share in the prior year period.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

Micromet second-quarter 2010 total revenues increase to $6.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

Cornerstone Therapeutics Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

First Edition: August 5, 2010

Today's health policy headlines examine the solvency of Medicare and Social Security; the momentum of legislation in Congress to provide states with Medicaid assistance; and the impact of Missouri's ballot challenge to health reform.

5 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

Medical News

Melanoma risk rises with the use of sunbeds: Study

Australia has highest rates of type 1 diabetes among children

Anti-vaccine group accused of unauthorized fundraising

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Ligand second-quarter net loss reduces to $0.3 million

Biovail second-quarter total revenues increase 23% to $238.8 million

WebMD intends to commence share repurchase program

Incyte second-quarter total revenues increase to $49.8 million

Sunrise Senior Living reports net income of $46.3 million for second-quarter 2010

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Harvard Bioscience second-quarter revenues increase 43.5% to $25.9 million

Biovail declares quarterly dividend of US$0.095

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Micromet second-quarter 2010 total revenues increase to $6.5 million

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

First Edition: August 5, 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News